By now, the complexity of COVID-19 is well known, if not well understood. One of the mysteries is so-called brain fog, or cognitive issues such as confusion or forgetfulness that occur as a result of Long Covid. New research is quantifying this. Heres a look at that story and other research news.
COVID-19 Cognitive Impairment Equal to 20 Years of Aging
A study from theUniversity of CambridgeandImperial College Londonfoundthat cognitive impairment caused by severe COVID-19 is similar to that sustained between 50 and 70 years of age. Another way of putting it is that it was equal to losing 10 IQ points. The research came out of the NIHR COVID-19 BioResource and found the effects were still detectable more than six months after acute illness, and recovery is at best gradual. The research was published inThe Lancet'spublicationeClinicalMedicine.
Cognitive impairment is common to a wide range of neurological disorders, including dementia, and even routine aging, but the patterns we saw the cognitive fingerprint of COVID-19 was distinct from all of these, said Dr. David Menon, M.D. from the Division of Anaesthesia at the University of Cambridge, the studys senior author. We followed some patients up as late as ten months after their acute infections, and were able to see a very slow improvement. While this was not statistically significant, it is at least heading in the right direction, but it is very possible that some of these individuals will never fully recover.
The reason behind the cognitive deficits seen with COVID-19 is not well understood. One theory is that direct viral infection may be to blame, but scientists dont believe it is a major cause. They think it is more likely that a combination of factors is involved, including poor oxygen and blood supply to the brain, blockage of large or small blood vessels from clotting and microscopic bleeds. Emerging evidence suggests the most significant factor may be damage from the bodys own inflammatory and immune response.
Repairing Tendons with Silk Proteins
Tendon injuries take a long time and often dont heal completely. Some of this is related to the relative lack of blood flow to the tendons and the fact they are soft tissues connected to stiff bones. Damage often changes the connective tissue from a linear to a kinked formation.
Investigators with the Terasaki Institute for Biomedical Innovationtestedthe use of biomaterial scaffolds to generate new tendon tissue. They started with silk fibroin, a silk protein generated by the Bombyx mori silkworm. It is used in silk fabrics and optical and electrical devices, and in several biomedical applications, including sutures and bioengineered ligaments, bone and corneal tissue.
They paired silk fibroin with GelMA, a gelatin-based, water-retaining gel. The mixtures were seeded with mesenchymal stem cells. They found that cell viability and proliferation and MSC gene activity were significantly increased, showing more than an 80% attachment rate. They also tested them on live rats with injured Achilles tendons, and the new technology accelerated healing with reduced injury sites and the formation of well-aligned, densely packed tendon fibers and remodeled muscle components.
Decreased Sedentary Time Mitigates Risk of Type 2 Diabetes & CV Disease
Research from the University of Turku in Finlandfoundthat decreasing the amount of time youre sedentary can mitigate the risk of type 2 diabetes and cardiovascular diseases. This is a slightly different lens than the association of exercise with decreased risk of diabetes and CV disease in that it looked at reducing the intervention groups time sitting by one hour per day by increasing standing and light-intensity physical activity.
The control group was to keep their typical habits and sedentary lifestyle. The groups were measured by wearing accelerometers for the entire three-month period. The intervention group decreased sedentary time by 50 minutes per day on average, typically by increasing the amount of light- and moderate-intensity physical activity. The study observed benefits in health outcomes associated with blood sugar regulation, insulin sensitivity and liver health.
Nanotechnology Visualizes RNA Structure at Near-Atomic Resolution
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical Schooldevelopeda new approach, ROCK, that uses an RNA nanotechnological technique to visualize RNA structure at near-atomic resolution. ROCK stands for RNA oligomerization-enabled cryo-EM via installing kissing loops. It allows for assembly of identical RNA molecules into a highly organized structure. This decreases the individual RNA molecules flexibility and increases their molecular weight.
It allows for structural analysis of the contained RNA subunits using the cryo-electron microscopy (cryo-EM) technique. For proof-of-principle, they focused on a large intron RNA from Tetrahymena, a single-celled organism, and a small intron RNA from Azoarcus, a nitrogen-fixing bacterium in addition to the FMN riboswitch.
Autism-Linked Mutation Reversed in Brain Organoids with Gene Therapy
A study out of the University of California San Diego School of Medicineutilizedhuman brain organoids to test a gene therapy. A number of neurological and neuropsychiatric diseases, including autism spectrum disorders (ASD) and schizophrenia, are linked to Transcription Factor 4 (TCF4) mutations. TCF4 is an essential gene in brain development. The researchers focused on Pitt-Hopkins Syndrome, an ASD caused by mutations in TCF4.
Existing mouse models of the syndrome dont accurately mimic patients neural characteristics. As a result, the research team created a human research model of the disorder using stem cells to convert patients skin cells to develop into three-dimensional brain organoids. They found that the TCF4 mutation led to downstream dysregulation of SOX genes and the Wnt pathway. These molecular signals guide embryonic cells to multiply, mature into neurons, and migrate to the appropriate brain location.
They then tested two different gene therapies for recovering the functional gene in brain tissue. Both effectively increased TCF4 levels and corrected Pitt-Hopkins Syndrome characteristics at molecular, cellular and electrophysiological levels.
The fact that we can correct this one gene and the entire neural system reestablishes itself, even at a functional level, is amazing, Alysson R. Muotri, Ph.D. said, professor at UC San Diego School of Medicine, director of the UC San Diego Stem Cell Program and member of the Sanford Consortium for Regenerative Medicine.
The work took place at a prenatal stage of brain development. Children diagnosed with this syndrome do so typically several years later in the clinic. Clinical trials would be required to confirm if a later intervention would be safe and effective. The research group is currently optimizing its licensed gene therapy tools for a trial, which would use spinal injections of the genetic vector in hopes of recovering TCF4 brain function.
Originally posted here:
Research Roundup: COVID-19 Cognitive Impairment Equal to 20 Years of Aging - BioSpace
- Gene therapy research offers hope for people with chronic kidney disease - Medical Xpress - January 6th, 2025
- Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizers Decision to Cease Development of Giroctocogene... - January 6th, 2025
- JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy -... - January 6th, 2025
- Gene therapy targets the retina to treat eye disease - Nature.com - January 6th, 2025
- Sangamos Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact - BioSpace - January 6th, 2025
- How Increased Use of Gene Therapy Treatment for Sickle Cell Disease Could Affect the Federal Budget - Congressional Budget Office - January 6th, 2025
- The Future of Regulatory Processes in Cell and Gene Therapy - Pharmaceutical Executive - January 6th, 2025
- CGTLive's 2024 Pillars of Progress: Most-Watched Conference Interviews - CGTLive - January 6th, 2025
- Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes - Fierce Biotech - January 6th, 2025
- JCR Pharmaceuticals and Modalis Advance Joint Gene Therapy Research - TipRanks - January 6th, 2025
- JCR and Modalis Advance Joint Gene Therapy Research - TipRanks - January 6th, 2025
- Novartis Gene Therapy Shows Promise in Treating SMA - Yahoo Finance - January 6th, 2025
- Gene Therapy Market to Hit Valuation of US$ 42.26 Billion By 2033 | Astute Analytica - Yahoo Finance - January 6th, 2025
- Novartis gene therapy helps children with rare muscle disorder in study - Reuters - January 6th, 2025
- Capricor Puts Rolling BLA for DMD Cardiomyopathy Cell Therapy Deramiocel in Front of the FDA - CGTLive - January 6th, 2025
- Positive data could expand use of Novartis gene therapy for SMA - Yahoo Finance - January 6th, 2025
- Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership - MM+M Online - January 6th, 2025
- Cell Therapy and Gene Therapy CDMO Market to Reach USD 11.11 Billion by 2030 | Discover Growth Trends and Insights | Valuates Reports - PR Newswire - January 6th, 2025
- Struggling With Adoption, Sickle Cell Gene Therapy Manufacturers Embrace CMS Model - News & Insights - January 6th, 2025
- Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer - Contract Pharma - January 6th, 2025
- Researchers Create Gene Therapy with Potential to Treat Peripheral Pain ... - December 28th, 2024
- How CRISPR Is Changing Cancer Research and Treatment - December 28th, 2024
- Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease - December 28th, 2024
- 100 cell and gene therapy leaders to watch in 2025 - December 28th, 2024
- Can a new gene therapy reverse heart failure? - Futurity - December 28th, 2024
- Sustained visual improvements in LHON patients treated with AAV gene therapy - Medical Xpress - December 28th, 2024
- Nebraska Medicine administers novel gene therapy to first hemophilia ... - December 28th, 2024
- Gene Therapy for Cardiomyopathies Presents Promising Alternative to Current Treatment - Managed Healthcare Executive - December 28th, 2024
- Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia - Medpage Today - December 28th, 2024
- Caribou Overhyped Gene-Therapy Testing, Investor Class Suit Says - Bloomberg Law - December 28th, 2024
- WuXi AppTec sells off cell and gene therapy operations in US, UK - FirstWord Pharma - December 28th, 2024
- Top 5 Print Publication Articles of 2024 - Managed Healthcare Executive - December 28th, 2024
- Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease - Medpage Today - December 28th, 2024
- UPenn gene therapy pioneers biotech gets $34 million in funding - The Philadelphia Inquirer - December 28th, 2024
- PHC Corporation to present LiCellGrow at Advanced Therapies Week 2025 - Drug Target Review - December 28th, 2024
- The Evolution of Cell & Gene Therapy: Development and Manufacturing Insights and the Role of CDMOs - Pharmaceutical Technology Magazine - December 28th, 2024
- Pig kidney transplants, new schizophrenia drug: Here are 5 of the biggest medical breakthroughs in 2024 - ABC News - December 28th, 2024
- Cell Therapy Manufacturing Trends And Advancements Continuing In 2025 - BioProcess Online - December 28th, 2024
- Can Gene Therapy Treat Chronic Pain? - LabRoots - December 28th, 2024
- Driving innovation: India's foray into gene and cell therapies - The Economic Times - December 28th, 2024
- Governor Hochul Celebrates the Opening Of New York's First Cell and Gene Therapy Hub at Roswell Park Comprehensive Cancer Center in Buffalo - PR Web - December 19th, 2024
- GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation - Business Wire - December 19th, 2024
- Atsena completes dosing in part A of X-linked retinoschisis gene therapy trial - Healio - December 19th, 2024
- Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - StreetInsider.com - December 19th, 2024
- Ring Therapeutics lays off just under half of staff in 2nd wave of cuts this year, CEO set to step down - Fierce Biotech - December 19th, 2024
- Gov. Hochul celebrates opening of first cell and gene therapy hub in NYS - WIVB.com - News 4 - December 19th, 2024
- Muscular Dystrophy Association and Coalition to Cure - GlobeNewswire - December 19th, 2024
- Atsena Therapeutics Announces Dosing Completed in Part A of - GlobeNewswire - December 19th, 2024
- 'A milestone moment': Roswell Park celebrates opening New York's first cell and gene therapy hub - WKBW 7 News Buffalo - December 19th, 2024
- Gene therapy to prevent stillbirth and premature delivery developed - News-Medical.Net - December 19th, 2024
- Breaking through the blood-brain barrier - Science - December 19th, 2024
- Cell therapy weekly: partnerships for advancing cell and gene therapies - RegMedNet - December 19th, 2024
- Roswell Park Opens Cell, Gene Therapy Hub - WGRZ.com - December 19th, 2024
- Cartherics gets $300k grant to advance Cell and Gene Therapy development - ETHealthWorld - December 19th, 2024
- ELMCRx Solutions Offers Cell & Gene Therapy Support Through Partnership with Emerging Therapy Solutions (ETS) - Business Wire - December 19th, 2024
- Fueling the Future of Gene Therapies with Manufacturing Innovation, Upcoming Webinar Hosted by Xtalks - PR Web - December 19th, 2024
- Concinnity secures 3M Seed funding to advance AI-driven gene therapy safety - Tech.eu - December 19th, 2024
- Viral Vectors-Based Gene Therapy for Non-Human Primates Market to Reach Over USD 92.76 Million by 2034 - EIN News - December 19th, 2024
- The pharma industry's silence on RFK Jr., and efforts by parents to develop gene therapies for their children - STAT - December 19th, 2024
- Tenaya reports positive early data on heart gene therapy - Investing.com - December 19th, 2024
- Unraveling The Complexity Of Cell Therapy: Advancements And Challenges - Life Science Leader Magazine - November 27th, 2024
- Novartis wagers more than $1B on gene therapies for the nervous system - BioPharma Dive - November 27th, 2024
- Gene therapy for geographic atrophy in age-related macular degeneration: current insights - Nature.com - November 27th, 2024
- Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - STAT - November 27th, 2024
- At MGB's gene therapy institute, effort to win first venture capital investments continues - The Business Journals - November 27th, 2024
- Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy - Fierce Biotech - November 27th, 2024
- Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy - CGTLive - November 27th, 2024
- Why This Gene-Therapy Companys Stock Is Rising 228% - Yahoo! Voices - November 27th, 2024
- How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando - geneonline - November 27th, 2024
- RNA editing is the next frontier in gene therapy heres what you need to know - The Conversation - November 27th, 2024
- Assessment of gene therapy viral vectors in RPE cells - News-Medical.Net - November 27th, 2024
- Retinal organoids and RPE models for retinal gene therapy development - News-Medical.Net - November 27th, 2024
- China Vows to Bolster Gene Therapy Research in Key Biotech Hub - Bloomberg - November 27th, 2024
- Gene Therapy - Volume 31 Issue 11-12, November 2024 - Nature.com - November 27th, 2024
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire - November 27th, 2024
- Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News - November 27th, 2024
- New CRISPR system pauses genes, rather than turning them off permanently - Livescience.com - November 27th, 2024
- Liver-targeting gene therapy lowers mice whole-body SMA symptoms - SMA News Today - November 27th, 2024
- Bright breakthroughs: Real stories of beating rare disease - Science - November 27th, 2024
- Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA... - November 27th, 2024